CN102036684B - 用于光动力疗法和坏死肿瘤成像的rgd‑(细菌)叶绿素缀合物 - Google Patents

用于光动力疗法和坏死肿瘤成像的rgd‑(细菌)叶绿素缀合物 Download PDF

Info

Publication number
CN102036684B
CN102036684B CN200980115901.2A CN200980115901A CN102036684B CN 102036684 B CN102036684 B CN 102036684B CN 200980115901 A CN200980115901 A CN 200980115901A CN 102036684 B CN102036684 B CN 102036684B
Authority
CN
China
Prior art keywords
tumor
group
necrotic
purposes
rgd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980115901.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102036684A (zh
Inventor
A·舍茨
L·戈尔德谢德
Y·萨洛蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of CN102036684A publication Critical patent/CN102036684A/zh
Application granted granted Critical
Publication of CN102036684B publication Critical patent/CN102036684B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K51/0451—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. phorphine derivatives, bilirubin, biliverdine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
CN200980115901.2A 2008-02-27 2009-03-01 用于光动力疗法和坏死肿瘤成像的rgd‑(细菌)叶绿素缀合物 Expired - Fee Related CN102036684B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6429808P 2008-02-27 2008-02-27
US61/064298 2008-02-27
PCT/IL2009/000228 WO2009107139A1 (en) 2008-02-27 2009-03-01 Rgd-(bacterio)chlorophyll conjugates for photodynamic therapy and imaging of necrotic tumors

Publications (2)

Publication Number Publication Date
CN102036684A CN102036684A (zh) 2011-04-27
CN102036684B true CN102036684B (zh) 2017-06-09

Family

ID=40677556

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980115901.2A Expired - Fee Related CN102036684B (zh) 2008-02-27 2009-03-01 用于光动力疗法和坏死肿瘤成像的rgd‑(细菌)叶绿素缀合物

Country Status (15)

Country Link
US (1) US8815213B2 (cg-RX-API-DMAC7.html)
EP (2) EP2257309B1 (cg-RX-API-DMAC7.html)
JP (1) JP5620279B2 (cg-RX-API-DMAC7.html)
KR (1) KR101595138B1 (cg-RX-API-DMAC7.html)
CN (1) CN102036684B (cg-RX-API-DMAC7.html)
AU (1) AU2009219682B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0907791A2 (cg-RX-API-DMAC7.html)
CA (1) CA2717060C (cg-RX-API-DMAC7.html)
DK (1) DK2257309T3 (cg-RX-API-DMAC7.html)
ES (1) ES2764781T3 (cg-RX-API-DMAC7.html)
MX (1) MX2010009530A (cg-RX-API-DMAC7.html)
PT (1) PT2257309T (cg-RX-API-DMAC7.html)
RU (1) RU2518296C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009107139A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201006789B (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1968648T3 (en) 2005-12-16 2015-07-27 Amit Shachaf Diagnostic system for the detection and diagnosis of skin cancer
US9957293B2 (en) * 2006-08-23 2018-05-01 Yeda Research And Development Company Ltd. Conjugates of RGD peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses
WO2011020107A2 (en) * 2009-08-14 2011-02-17 Georgetown University Compositions and methods for detection and treatment of breast cancer
PL219569B1 (pl) 2010-02-19 2015-05-29 Peptaderm Spółka Z Ograniczoną Odpowiedzialnością Cykliczne tetrapeptydy i ich zastosowanie
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
KR101253709B1 (ko) * 2011-06-02 2013-04-12 경북대학교 산학협력단 분비형 표적 추적 융합 단백질
EP2774625B1 (en) * 2011-09-05 2017-04-12 Hiroshi Maeda Polymer-type fluorescent molecule probe
US9798856B2 (en) * 2012-03-21 2017-10-24 Koninklijke Philips N.V. Clinical workstation integrating medical imaging and biopsy data and methods using same
CN103705532B (zh) * 2012-10-08 2016-09-14 浙江海正药业股份有限公司 靶向胸苷激酶光敏剂及其药物组合物与治疗癌症的用途
EP3148583B1 (en) 2014-06-02 2020-04-29 Li-Cor, Inc. Phthalocyanine probes and uses thereof
CA2954463C (en) 2014-08-08 2023-11-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Photo-controlled removal of targets in vitro and in vivo
NZ731185A (en) 2014-10-29 2024-03-22 Bicyclerd Ltd Bicyclic peptide ligands specific for mt1-mmp
CA2969251C (en) * 2014-12-08 2023-08-15 Arash Zarrine-Afsar System and method for enhanced mass spectrometry imaging
JP6793122B2 (ja) * 2014-12-19 2020-12-02 ブラッコ・イメージング・ソシエタ・ペル・アチオニBracco Imaging S.P.A. 術中イメージング
PL3166606T3 (pl) * 2015-06-03 2018-10-31 Surgimab S.A.S. Koniugaty fluorescencyjne
ES2999358T3 (en) 2015-08-18 2025-02-25 Rakuten Medical Inc Phthalocyanine dye conjugates and their storage
WO2017049403A1 (en) 2015-09-22 2017-03-30 University Health Network System and method for optimized mass spectrometry analysis
EP3559018A1 (en) * 2016-12-23 2019-10-30 Bicyclerd Limited Peptide derivatives having novel linkage structures
MX2019007367A (es) * 2016-12-23 2020-01-27 Bicycletx Ltd Ligandos de peptido para enlace a mt1-mmp.
US10933134B2 (en) 2017-03-16 2021-03-02 Memorial Sloan Kettering Cancer Center Combination therapies for treatment of cancer
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Cd137に対して特異的な二環式ペプチドリガンド
EP3664892A4 (en) 2017-08-08 2021-04-28 Board of Trustees of Michigan State University TUNED LUMINESCENT ORGANIC SALT FOR ENHANCED IMAGING AND PHOTODYNAMIC THERAPY
JP6920931B2 (ja) * 2017-09-01 2021-08-18 富士フイルム株式会社 医療画像処理装置、内視鏡装置、診断支援装置、及び、医療業務支援装置
CA3091775A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
RU2700407C1 (ru) * 2018-07-23 2019-09-16 Михаил Тимофеевич Александров Способ лечения опухолевых и воспалительных заболеваний с применением фотодинамической терапии
CN111171030B (zh) * 2018-11-12 2022-11-22 浙江海正药业股份有限公司 细菌叶绿素衍生物及其制备方法
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
EP3897849A1 (en) 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
JP7744340B2 (ja) * 2019-12-05 2025-09-25 テンパス・エーアイ・インコーポレイテッド ハイスループット薬物スクリーニングのためのシステムおよび方法
CN116348476A (zh) 2020-08-03 2023-06-27 拜斯科技术开发有限公司 基于肽的接头
AU2021416188A1 (en) 2020-12-31 2023-07-06 Orlucent, Inc. Systems and methods for assessing tissue remodeling
CN112933252A (zh) * 2021-01-28 2021-06-11 厦门大学附属翔安医院 一种乳腺癌特异靶向分子探针及其制备方法和应用
CN115466311A (zh) * 2021-06-10 2022-12-13 首都医科大学 抗粘附迁移和侵袭的18β-甘草次酸-RGDK,其合成,抗癌转移活性和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1088210A (zh) * 1992-07-26 1994-06-22 耶达研究及发展有限公司 叶绿素、细菌叶绿素衍生物,它们的制备以及含有它们的药物组合物
WO1998010795A2 (en) * 1996-09-10 1998-03-19 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4121876A1 (de) 1991-07-02 1993-01-14 Scheer Hugo Modifizierte bakteriochlorophylle, verfahren zu ihrer herstellung und ihre verwendung
JPH07503944A (ja) 1991-11-22 1995-04-27 イエダ リサーチ アンド デベロツプメント カンパニー リミテツド Arg−gly−asp配列の非ペプチド代替物およびそれらからなる医薬組成物
US6147195A (en) 1993-07-26 2000-11-14 Yeda Research And Development Co., Ltd. Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them
US5789433A (en) * 1995-01-17 1998-08-04 Quadra Logic Technologies, Inc. Green porphyrins as immunomodulators
IL116126A0 (en) 1995-11-24 1996-01-31 Yeda Res & Dev Process for the preparation of bacteriochlorophyllis some novel compounds of this type and pharmaceutical compositions comprising them
US6576239B1 (en) 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
DE19756773A1 (de) * 1997-12-19 1999-06-24 Dade Behring Marburg Gmbh Neues Verfahren und Diagnosemittel zur Hämostase-Diagnostik
PL201172B1 (pl) 1998-12-09 2009-03-31 Yeda Res & Dev Pd-Bakteriofeoforbid, sposób jego wytwarzania, kompozycja farmaceutyczna zawierająca go i jego zastosowanie
IL133253A0 (en) 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
US7045117B2 (en) 1999-12-01 2006-05-16 Yeda Research And Development Co. Ltd. Method for tumor diagnosis comprising administering of palladium-substituted bacteriochlorophyll derivatives
IL152900A0 (en) 2002-11-17 2003-06-24 Yeda Res & Dev Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses
EP1753457B8 (en) 2004-06-07 2016-09-21 Yeda Research And Development Co., Ltd. Cationic bacteriochlorophyll derivatives and uses thereof
US20070258908A1 (en) * 2006-04-27 2007-11-08 Lanza Gregory M Detection and imaging of target tissue
RU2450018C2 (ru) * 2006-08-23 2012-05-10 Йеда Рисерч Энд Диверлопмент Ко. Лтд Конъюгаты rgd-пептидов и фотосенсибилизаторов порфирина или (бактерио)хлорофилла и их применение
US20110223102A1 (en) * 2007-09-14 2011-09-15 Health Research, Inc. Multimodality agents for tumor imaging and therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1088210A (zh) * 1992-07-26 1994-06-22 耶达研究及发展有限公司 叶绿素、细菌叶绿素衍生物,它们的制备以及含有它们的药物组合物
WO1998010795A2 (en) * 1996-09-10 1998-03-19 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same

Also Published As

Publication number Publication date
EP2712627A3 (en) 2014-04-16
BRPI0907791A2 (pt) 2015-08-04
AU2009219682B2 (en) 2015-06-18
KR20100127798A (ko) 2010-12-06
JP2011513298A (ja) 2011-04-28
EP2257309B1 (en) 2019-10-16
JP5620279B2 (ja) 2014-11-05
RU2010139461A (ru) 2012-04-10
CA2717060C (en) 2016-11-01
EP2712627A2 (en) 2014-04-02
CN102036684A (zh) 2011-04-27
MX2010009530A (es) 2010-11-30
US20110064658A1 (en) 2011-03-17
AU2009219682A1 (en) 2009-09-03
ZA201006789B (en) 2012-01-25
US8815213B2 (en) 2014-08-26
WO2009107139A1 (en) 2009-09-03
EP2257309A1 (en) 2010-12-08
ES2764781T3 (es) 2020-06-04
RU2518296C2 (ru) 2014-06-10
CA2717060A1 (en) 2009-09-03
KR101595138B1 (ko) 2016-02-18
DK2257309T3 (da) 2020-01-20
PT2257309T (pt) 2020-01-22

Similar Documents

Publication Publication Date Title
KR101595138B1 (ko) 괴사종양의 광역학요법 및 영상용 알지디(박테리오)클로로필 컨쥬게이트
JP6177013B2 (ja) Rgdペプチドとポルフィリン又は(バクテリオ)クロロフィル光合成剤とのコンジュゲート及びその使用
ES2861528T3 (es) Colorantes del NIR dirigidos al PSMA y sus usos
KR20230129261A (ko) 섬유모세포 활성화 단백질 리간드를 포함하는 화합물및 그의 용도
KR20220032078A (ko) 섬유모세포 활성화 단백질 리간드를 포함하는 화합물 및 그의 용도
CA3035542A1 (en) Psma-targeted nir dyes and their uses
JP6793122B2 (ja) 術中イメージング
Zhou et al. Targeting tumor hypoxia: a third generation 2-nitroimidazole-indocyanine dye-conjugate with improved fluorescent yield
Turnbull et al. A dual modality 99mTc/Re (I)-labelled T140 analogue for imaging of CXCR4 expression
WO2013106824A1 (en) Epherin receptor targeting agents
Liu et al. A follicle-stimulating hormone receptor-targeted near-infrared fluorescent probe for tumor-selective imaging and photothermal therapy
Sanz-Villafruela et al. Bombesin-Targeted Delivery of β-Carboline-Based Ir (III) and Ru (II) Photosensitizers for a Selective Photodynamic Therapy of Prostate Cancer
Wu et al. Hypoxia-responsive theranostic nanoplatform with intensified chemo-photothermal/photodynamic ternary therapy and fluorescence tracing in colorectal cancer ablation
Miranda Cona et al. Necrosis avidity of organic compounds: a natural phenomenon with exploitable theragnostic potentials
CA3206250A1 (en) Psma-targeting ligands for multimodal applications
NZ551210A (en) Peptide-based compounds
US11213597B2 (en) Kinin-based theranostic probes for solid cancers and uses thereof
Deng et al. Self‐Assembled PSMA‐Targeted Nanoparticles Enhanced Photodynamic Therapy in Prostate Cancer
WO2021155151A1 (en) Multivalent ligands targeting cell surface receptors and force measurement platform for making the same
Ali Peptide Targeted Photodynamic Therapy
Habimana-Griffin Quantitative Fluorescence Imaging for Investigation and Treatment of Disease
Turnbull The Development of Metal Complexes as Components of Fluorescent and Nuclear Imaging Probes
Gilson Photodynamic Therapy: Agents and Mechanisms
Broughton Characterisation of Duramycin as an Anti-cancer Agent
Mieog et al. Intraoperative near-infrared fluorescence imaging of colorectal metastases targeting integrin αβ expression in a syngeneic rat model

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170609

CF01 Termination of patent right due to non-payment of annual fee